| Name | Title | Contact Details |
|---|---|---|
Bradford Cross |
Chief Technology Officer | Profile |
Bradford Cross |
Chief Technology Officer | Profile |
Tosk is a Santa Cruz, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies. Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival. Our technology, originated in the laboratories of Drs. Amato Giaccia and his colleagues at Stanford University, uses genetic screening to identify critical targets for the development of therapeutic molecules for cancer therapy while sparing healthy cells. This strategy is designed to enable us to interrupt oncogenic signals and, using our high-affinity decoy receptors, outcompete cancer`s ability to grow, metastasize and acquire resistance to treatments. We believe our unique cancer therapies may hold promise as a monotherapy or in combination with other cancer treatments, augmenting the anti-tumor activity of radiotherapy, chemotherapy, immuno-therapeutics and cancer vaccines. By targeting advanced or metastatic disease, our approach has the potential to significantly improve survival rates while simultaneously reducing toxicity in cancer patients.
AiLife Diagnostics is a CAP/CLIA laboratory that provides end-to-end genomic testing, interpretation services, and NGS analysis tool.
Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has approximately two hundred employees in Seattle, Cambridge, and South San Francisco. In 2019, we raised capital to enable our broad vision, began to acquire technology and establish an IP estate across cell and gene therapy, and made significant progress validating our cell and gene therapy platforms. Growing from this foundation, we intend to push forward our platforms and product pipeline in 2020 and beyond.